#TalkingRegMed episode 6: Brexit with Matthew Durdy, Cell and Gene Therapy Catapult

In this episode of #TalkingRegMed, Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult, explains the effect of Brexit on cell therapy development in the UK.

Go to the profile of RegMedNet
Mar 13, 2018
Upvote 0 Comment

In this episode of #TalkingRegMed, hear from Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult, on how Brexit may effect the cell therapy industry in the UK. In particular, he discusses what other avenues are being explored to ensure Britain remains on the world stage in this industry.

Watch more #TalkingRegMed

Go to the profile of RegMedNet


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.